FDAnews Drug Daily Bulletin

AVALON PHARMACEUTICALS ANNOUNCES EXPIRATION OF THE SANOFI-AVENTIS AGREEMENT

Dec. 27, 2005
A A

Avalon Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the expiration of its agreement with sanofi-aventis. The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets. The agreement expired as a result of sanofi- aventis' decision not to advance targets that were a focus of the collaboration for further validation.

Yahoo News (http://biz.yahoo.com/prnews/051221/nyw135.html?.v=32)